The objective of this study was to develop an in vitro-in vivo correlation (IVIVC) model for hydrophilic matrix sustained-release (SR) Metoclopramide formulations. The in vitro release characteristics of the drug were determined using USP apparatus II at 50 rpm, pH 6.8. In vivo plasma concentrations and pharmacokinetic parameters in healthy human subjects were obtained after administering oral dose, developed SR formulations and marketed immediate-release (IR) products. The similarity factor f2 was used to compare the dissolution data. The IVIVC model was developed using pooled fraction dissolved and fraction absorbed of developed SR formulations i.e. fast, medium and slow release and marketed immediate-release (IR) products. An in vitro-in vivo correlation (IVIVC) was established for sustained release tablet by deconvolution using data from an immediate-release treatment as the characteristic response. To assess the correlation between in vitro dissolution uniqueness and in vivo absorption performance of Metoclopramide sustained release (SR) and immediate release (IR) tablet in human subjects. The established IVIVC was evaluated internally by predicting data used to develop and externally by predicting data not originally included in developing the IVIVC model. The observed low prediction errors for Cmax and AUC demonstrated that the Metoclopramide IVIVC model was valid.
INTRODUCTION
In vitro in vivo correlation is a predictive mathematical model describing the relationship between the in vitro property of dosage form and in vivo response. In vitro property is a rate of drug release and in vivo response is the amount of drug absorbed. In vitro in vivo correlation plays a vital role in the early stage of product development, substitute for in vivo bioavailability and to support biowaivers, to facilitate scale-up and post approval changes, and to set significant dissolution specifications. In vitro in vivo correlation is established to facilitate dissolution test to be used as surrogacy for bio study and it benefit the pharmaceutical manufacturer in terms of time and cost on bioequivalence study. [7] [8] [9] [10] In vitro in vivo correlation models will be useful for optimizing the SR (sustained release) dosage forms, otherwise predict in vivo performance of the SR dosage forms based on in vitro dissolution data. The FDA guidance has identified three In vitro in vivo correlation models: namely, level A, B, and C models. 6 Numerous investigations have been undertaken to develop In vitro in vivo correlation models, a level A correlation utilize the complete time course of in vitro dissolution and in vivo input and recognized model of choice for achieve biowaivers or setting of dissolution specifications. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, level B and C models may be used in the initial stages of formulation development to inspect level A In vitro in vivo correlation models shall be used. 6 The present work aim was to develop and establish the internal and external predictability of level A In vitro in vivo correlation models for the three Metoclopramide sustained release and one immediate release formulation were evaluated. The rationale behind the study was develop Metoclopramide In vitro in vivo correlation models, so that it can serve as a surrogate for in vivo bioavailability and to support biowaivers and which in turn reduce the cost of the optimization process.
MATERIALS AND METHODS

Chemicals and Reagents
Metoclopramide Hydrochloride & Cisapride were supplied by Adcock Ingram Healthcare Pvt. Ltd. (Bangalore, India). The HPMCK100M supplied by Colorcon Asia Pvt Ltd. (Goa, India). Avicel, Magnesium stearate and talc were procured from local supplier.
Formulation of Tablets
Sustained release formulations, each tablet containing 10 mg of Metoclopramide hydrochloride, prepared by weighing the amount of active ingredients, polymers (HPMC), avicel magnesium stearate and talc in different ratio and blended to get homogeneous mixture. Tablets were prepared by direct compression on a single punch machine (10 mm bi-flat round shaped punches). The Metoclopramide hydrochloride formulations were prepared at three different release rates i.e. fast, medium and slow sustained release tablets. [1] [2] [3] In vitro release studies
The dissolution performance of Metoclopramide hydrochloride determined by using a USP dissolution apparatus 2 (paddle method). The release studies were performed in pH 1. 
Clinical pharmacokinetic study
This was an open-label, single dose, four-treatment crossover study by using six healthy volunteers under fasting condition. Subjects were given informed consent prior to participation and study was approved by the ethics committee. Subjects randomly allocated treatment as per the randomization schedule, such a way all subjects would receive four formulations upon completion of the study. Blood samples were collected at predeter- Washout period of at least 07 days between dosage. 4 Plasma samples were stored in an upright position below -20°C till completion of analysis. Plasma samples were estimated for Metoclopramide by using a validated LCMS/MS with liquid liquid extraction method. Chromatographic separation achieved on a Eclipse XDB C18 (100 mm x 4.6 mm, 3.5 µm) column using a mobile phase consisting of methanol and ammonium acetate buffer 5 mM (50:50 v/v). The RT of Metoclopramide hydrochloride and internal standard was 1.1 and 2.1 minutes. The method was validated over a concentration range of 0.532 ng/mL to 201.005 ng/mL for Metoclopramide. The lower limit of quantization (LLLQ) was established at 0.532 ng/mL for Metoclopramide. Plasma sample analysis were performed by using a validated high performance liquid chromatography mass spectrometric method. 
Dissolution data analysis
The in vitro drug release was calculated by using similarity factor (f2) and dissolution profile of all formulations were determined by scheming the cumulative percent of Metoclopramide hydrochloride versus time. The in-vitro drug release profile of the three SR formulations were compared using the similarity factor (f2) as mentioned in the following equation:
where R t and T t are the percent dissolved at each time point for the reference and test product respectively. The f 2 equation is a logarithmic transformation of the sum of squares of the difference between test and reference formulation. The f 2 average difference between 0 and 100. If the value of f 2 is less than 50 dissolution profiles wee considered dissimilar. If f 2 value 50 suggests that the reference and test product release curves differ by at least 10% and f 2 values greater than 50 (between 50 and 100) make sure similarity or uniformity between two dissolution profiles. The percent drug dissolved versus time calculated by using weibull method.
Clinical pharmacokinetic data analysis
The plasma concentration-time data were estimated by using Phoenix 6.4.0 version software. Maximum plasma concentration observed for the subject was Cmax and time to take place was Tmax. Area under the plasma concentration-time profile estimated by the trapezoidal method. The rate constant (K) describing the terminal slope of mean plasma concentration-time profile was determined by linear least squares fitting of the natural logarithm (Ln) transformed terminal plasma concentrations vs. time to the equation for a straight line. The elimination rate constant was estimated by linear regression of linear portion of logarithm of the concentrations versus time. The percent of drug absorbed versus time estimated by using deconvolution technique.
In vitro In vivo Correlation
Level A correlation was developed as mentioned in the FDA and USP guidelines by using the data obtained in the in vivo study. The percent of drug dissolved was estimated by plotting time points against the drug release profile and the fraction of drug absorbed was derived by using Wagner-Nelson method. Linear regression analysis was used to inspect the relationship between percent of drug dissolved and percent of drug absorbed. The correlation developed by using in vitro and in vivo data.
IVIVC Model validation
The objective is to validate the prediction of in vivo performance from in vitro data. The validation explain how well the developed IVIVC model predicts the in vivo data when in vitro data applied. The percentage prediction error of Cmax and AUC estimated by using equation mentioned below:
observed predicted % PE 100 observed Internal validation includes the cross validation of one formulation with other three formulation used for IVIVC model development. Internal validation is optional for IVIVC analysis and provides base for the suitability of the model. and external validation is based on how good IVIVC predicts the additional set of data. As described on FDA guidance IVIVC model is valid when the internal predictability (absolute PE) of Cmax and AUC for each formulation should not exceed 15% and with the average should not exceed 10% (percentage), and for external validation the prediction errors of Cmax and AUC should not exceed 10% and values between 10% to 20% and more than20% is not acceptable.
RESULTS
In vitro studies
The in vitro drug release studies were conducted at different pH conditions (namely pH 1.2, 4.5, 5.5, 6.8, 7.4) to check the release and to select the optimum pH condition for the drug. The percentage fraction dissolved for Metoclopramide hydrochloride of marketed immediate release, fast, medium and slow sustained release tablets and percentage drug release at different time points are presented in Table 1 & Figure 1 .
DISCUSSION
In vitro and in vivo studies were performed for the developed sustained release formulation i.e. fast, medium and slow sustained release tablets. Dissolution studies were performed at pH 1.2 for 50 rpm, the release of the drug was unfinished and showed maximum up to 31.98%, pH 4.5 at 50 rpm, the drug release was slow over the last time point and maximum release up to 85.64% pH 5.5 at 50 rpm drug release was homogeneous and observed 94. Figure 1 . The f2 values are calculated for fast versus slow f2 value is 47.12 at the borderline, fast versus medium and medium versus slow formulation observed higher than 50 confirms and for formulation that these dissolution mediums are indistinguishable and ensures sameness or equivalence between the two dissolution profiles. The mean Metoclopramide pharmacokinetic parameters AUClast and AUCINF_obs were reasonably higher for marketed release tablet compare to the test formulation. Followed by lower elimination rate and higher half life for fast and medium release observed compare to slow release and marketed tablet. The mean pharmacokinetic results are presented in Figure 2 and Table 2 . A Level A correlation was developed by building IVIVC plot using percent dissolved versus percent absorbed for all three formulations. The slope of the best-fit line was Figure 3 , 4 and 5 respectively. A good linear regression relationship was observed.
IVIVC Validation
The percentage prediction errors for C max and AUC were calculated by using marketed Metoclopramide hydrochloride immediate release tablets as a target formulation. The C max prediction errors for the fast, medium and slow formulations were found to be -12.356%, -16.049% and -24.612% respectively and AUC values were -22.484%, 7.461% and 7.349% for respectively refer The validation of internal and external predictability was successfully accomplished. The prediction error for C max and AUC was within the specified limit as per the FDA guidance hence, the IVIVC is well thought-out as validated both in terms of internal and external validation. Thus, this IVIVC model may be used during process change, site change, to reduce the number of human studies during the formulation development and serve as a surrogate for in vivo bioavailability, to support biowaivers, to support dissolution methods and specification settings. It can also assist in quality control for during the scale-up and postapproval changes (SUPAC).
CONCLUSION
The developed in vitro methods can act as a surrogate for in vivo bioavailability study and support biowaivers, assist in quality control during scale-up and post-approval changes. It may be useful in predicting the variation in site change, process changes and to predict the absorption performance of Metoclopramide Hydrochloride products with different release rates. 
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